Valuation: Amicus Therapeutics

Market Cap 4.55B 4.12B 3.81B 3.44B 6.48B 429B 6.71B 45.81B 18.17B 229B 17.07B 16.71B 727B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.26B 3.94B 3.55B 6.7B 443B 6.93B 47.31B 18.76B 237B 17.63B 17.26B 751B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%+1.65% - - 4.55B
-1.29%-1.76%+51.98%+64.66% 66.33B
-0.09%+2.79%+10.75%+95.02% 60.62B
+0.63%+1.64%+24.25%+89.70% 55.5B
-0.22%-0.33%+10.44%+119.88% 47.58B
-0.39%-5.34%+22.13%+28.89% 43.69B
-1.88%-15.55%+144.48%+695.46% 37.27B
+0.23%+1.66%+14.85%+49.06% 36.57B
+2.35%-3.61%+78.64%+60.70% 32.22B
+2.01%+6.68%-37.25%+406.79% 26.58B
Average +0.33%+0.33%+35.59%+178.91% 45B
Weighted average by Cap. +0.02%+0.33%+35.39%+153.74%

Financials

2024 2025
Net sales 528M 479M 443M 400M 753M 49.81B 779M 5.32B 2.11B 26.61B 1.98B 1.94B 84.46B 634M 575M 532M 480M 904M 59.8B 936M 6.39B 2.53B 31.94B 2.38B 2.33B 101B
Net income -56.11M -50.84M -47.03M -42.43M -79.96M -5.29B -82.78M -565M -224M -2.83B -211M -206M -8.97B -27.11M -24.57M -22.72M -20.5M -38.64M -2.56B -40M -273M -108M -1.37B -102M -99.58M -4.33B
Net Debt 194M 176M 162M 146M 276M 18.26B 286M 1.95B 773M 9.76B 727M 711M 30.97B 149M 135M 125M 113M 212M 14.03B 220M 1.5B 594M 7.5B 559M 547M 23.79B
Logo Amicus Therapeutics
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
-